 Connection
Peter Anderson to United States
This is a "connection" page, showing publications Peter Anderson has written about United States.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.249 |
|
|
|
-
Castillo-Mancilla JR, Aquilante CL, Wempe MF, Smeaton LM, Firnhaber C, LaRosa AM, Kumarasamy N, Andrade A, Baheti G, Fletcher CV, Campbell TB, Haas DW, MaWhinney S, Anderson PL. Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342). J Antimicrob Chemother. 2016 06; 71(6):1609-18.
Score: 0.038
-
Wempe MF, Anderson PL. Atazanavir metabolism according to CYP3A5 status: an in vitro-in vivo assessment. Drug Metab Dispos. 2011 Mar; 39(3):522-7.
Score: 0.027
-
Silverberg JI, Anderson P, Cappelleri JC, Piercy J, Levenberg ME, Myers DE, Gerber RA. Burden of mild and moderate atopic dermatitis in adults: results from a real-world study in the United States. Arch Dermatol Res. 2025 Mar 12; 317(1):556.
Score: 0.018
-
Horvath KJ, Helm JL, Black A, Chase GE, Ma J, Klaphake J, Garcia-Myers K, Anderson PL, Baker JV. A Pilot Randomized Controlled Trial of an mHealth Intervention to Improve PrEP Adherence Among Young Sexual Minority Men. AIDS Behav. 2024 Aug; 28(8):2804-2820.
Score: 0.017
-
Blumenthal J, Jain S, He F, Amico KR, Kofron R, Ellorin E, Stockman JK, Psaros C, Ntim GM, Chow K, Anderson PL, Haubrich R, Corado K, Moore DJ, Morris S, Landovitz RJ. Results from a Pre-exposure Prophylaxis Demonstration Project for At-risk Cisgender Women in the United States. Clin Infect Dis. 2021 10 05; 73(7):1149-1156.
Score: 0.014
-
Edupuganti S, Mgodi N, Karuna ST, Andrew P, Rudnicki E, Kochar N, deCamp A, De La Grecca R, Anderson M, Karg C, Tindale I, Greene E, Broder GB, Lucas J, Hural J, Gallardo-Cartagena JA, Gonzales P, Frank I, Sobieszczyk M, Gomez Lorenzo MM, Burns D, Anderson PL, Miner MD, Ledgerwood J, Mascola JR, Gilbert PB, Cohen MS, Corey L. Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody. J Acquir Immune Defic Syndr. 2021 05 01; 87(1):671-679.
Score: 0.014
-
Whitfield DL, Beauchamp G, Fields S, Nelson L, Magnus M, Dacus JD, Paul J, Anderson P, Wheeler D. Risk compensation in HIV PrEP adherence among Black men who have sex with men in HPTN 073 study. AIDS Care. 2021 05; 33(5):633-638.
Score: 0.013
-
Leech AA, Biancarelli D, Aaron E, Miller ES, Coleman JS, Anderson PL, Nkwihoreze H, Condron B, Sullivan M. HIV Pre-Exposure Prophylaxis for Conception Among HIV Serodiscordant Couples in the United States: A Cohort Study. AIDS Patient Care STDS. 2020 07; 34(7):295-302.
Score: 0.013
-
Bauermeister JA, Golinkoff JM, Carballo-Di?guez A, Giguere R, L?pez D, Hoesley CJ, Chen BA, Anderson P, Dezzutti CS, Strizki J, Sprinkle C, Heard F, Hall W, Jacobson C, Berthiaume J, Mayo A, Richardson BA, Piper J. A Mixed-Methods Study Examining Adherence to and Acceptability of Intravaginal Rings for HIV Prevention: Behavioral Results of MTN-027. AIDS Behav. 2020 Feb; 24(2):607-616.
Score: 0.013
-
Tang EC, Vittinghoff E, Anderson PL, Cohen SE, Doblecki-Lewis S, Bacon O, Coleman ME, Buchbinder SP, Chege W, Kolber MA, Elion R, Shlipak M, Liu AY. Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project. J Acquir Immune Defic Syndr. 2018 02 01; 77(2):193-198.
Score: 0.011
-
Baxi SM, Vittinghoff E, Bacchetti P, Huang Y, Chillag K, Wiegand R, Anderson PL, Grant R, Greenblatt RM, Buchbinder S, Gandhi M, Liu AY. Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial. PLoS One. 2018; 13(1):e0190118.
Score: 0.011
-
Koss CA, Hosek SG, Bacchetti P, Anderson PL, Liu AY, Horng H, Benet LZ, Kuncze K, Louie A, Saberi P, Wilson CM, Gandhi M. Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States. Clin Infect Dis. 2018 01 06; 66(2):213-219.
Score: 0.011
-
Hosek SG, Landovitz RJ, Kapogiannis B, Siberry GK, Rudy B, Rutledge B, Liu N, Harris DR, Mulligan K, Zimet G, Mayer KH, Anderson P, Kiser JJ, Lally M, Brothers J, Bojan K, Rooney J, Wilson CM. Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States. JAMA Pediatr. 2017 11 01; 171(11):1063-1071.
Score: 0.011
-
Gandhi M, Murnane PM, Bacchetti P, Elion R, Kolber MA, Cohen SE, Horng H, Louie A, Kuncze K, Koss CA, Anderson PL, Buchbinder S, Liu A. Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomen. AIDS. 2017 Oct 23; 31(16):2245-2251.
Score: 0.011
-
Hosek SG, Rudy B, Landovitz R, Kapogiannis B, Siberry G, Rutledge B, Liu N, Brothers J, Mulligan K, Zimet G, Lally M, Mayer KH, Anderson P, Kiser J, Rooney JF, Wilson CM. An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM. J Acquir Immune Defic Syndr. 2017 01 01; 74(1):21-29.
Score: 0.010
-
Liu A, Glidden DV, Anderson PL, Amico KR, McMahan V, Mehrotra M, Lama JR, MacRae J, Hinojosa JC, Montoya O, Veloso VG, Schechter M, Kallas EG, Chariyalerstak S, Bekker LG, Mayer K, Buchbinder S, Grant R. Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study. J Acquir Immune Defic Syndr. 2014 Dec 15; 67(5):528-37.
Score: 0.009
-
Kudinha T, Johnson JR, Andrew SD, Kong F, Anderson P, Gilbert GL. Genotypic and phenotypic characterization of Escherichia coli isolates from children with urinary tract infection and from healthy carriers. Pediatr Infect Dis J. 2013 May; 32(5):543-8.
Score: 0.008
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|